This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Riken Corporation, Ambicion Co., Ltd.. Active years: 2016-2023.
Company Filing History:
2 out of 886 
1 out of 1 Years Active: 2016-2023
Title: Tomokuni Shigeura: Innovator in NKT Cell Activation Technology
Introduction
Tomokuni Shigeura is a notable inventor based in Wako, Japan. He has made significant contributions to the field of immunology, particularly in the activation of NKT cells. With a total of 2 patents, his work has the potential to impact therapeutic approaches for various diseases.
Latest Patents
Shigeura's latest patents include a technology for efficient activation of NKT cells. This invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and induces proliferation, IFN-γ production, and cytotoxic activity. The method involves culturing isolated CD14 positive cells in a medium containing an NKT cell ligand and GM-CSF, while being substantially free of IL-4. Additionally, he has developed a hydroxylated KRN7000 analogue, which provides a compound that can be used to treat autoimmune diseases or suppress immunity.
Career Highlights
Throughout his career, Shigeura has worked with prominent organizations such as Riken Corporation and Ambicion Co., Ltd. His experience in these companies has allowed him to refine his research and contribute to advancements in medical technology.
Collaborations
Some of his notable coworkers include Masaru Taniguchi and Minako Aihara. Their collaborative efforts have further enhanced the research and development of innovative solutions in the field.
Conclusion
Tomokuni Shigeura's contributions to NKT cell activation technology exemplify the impact of innovative research in immunology. His patents reflect a commitment to advancing medical science and improving treatment options for patients.